Salesforce vs. Synopsys: Which Technology Stock Is a Better Buy in 2026?

The article favors Synopsys over Salesforce for a long-term portfolio, citing Synopsys's position in chip-design software and faster growth: FY2025 revenue rose 15.1% to about $7.1 billion, versus Salesforce FY2026 revenue growth of 9.6% to nearly $41.5 billion. Synopsys reported Q3 FY2026 revenue of $2.48 billion, beat earnings estimates, and raised its full-year outlook, though growth included a full quarter of acquisition contribution. Salesforce reported Q2 FY2027 revenue growth of 11% and free cash flow growth of 81%, but the article says part of its earnings beat came from an investment gain; Synopsys trades at higher valuation multiples (30.0x forward P/E and 9.2x sales versus 14.8x and 4.6x for Salesforce).

Analysis

The key question is not whether AI lifts demand for both companies, but where growth is already priced and how cleanly it converts to shareholder value. Synopsys has a genuine EDA chokepoint, but “every AI chip” is too absolute: large customers can use multiple tools, and export controls or project delays can interrupt spend. More importantly, acquisition contribution and integration now cloud the read-through from reported growth to organic demand, while added debt raises downside sensitivity if semiconductor design budgets soften. At its premium multiple, SNPS needs sustained organic growth and deleveraging—not merely AI exposure.

Salesforce is the less expensive expression of enterprise AI, but Agentforce adoption is not yet equivalent to incremental paid usage or durable seat expansion. Microsoft is a distribution and bundling risk; CRM’s investment gains also make reported earnings a noisy operating signal. Its substantial SBC means cash flow should be assessed after dilution, not treated as wholly distributable.

Over days, sentiment may favor SNPS on AI enthusiasm; over 1–3 months, organic bookings, acquisition integration, and leverage are the decisive catalysts. Over 6–18 months, SNPS retains stronger structural exposure, while CRM’s upside depends on proving AI monetization. The contrarian opportunity is that investors may be paying too much for SNPS’s structural advantage before its post-acquisition economics are transparent.

Key Decisions for Investors

• Avoid chasing SNPS on the AI narrative alone. Consider a staged entry after results clarify organic growth, bookings, and acquisition-related debt progress; the thesis weakens if organic demand decelerates or leverage fails to trend down.
• For a valuation-conscious relative expression, consider a modest, beta-adjusted long CRM / short SNPS pair rather than a standalone short of SNPS. It benefits if the valuation gap narrows while retaining exposure to enterprise software and AI; unwind if SNPS demonstrates sustained organic acceleration and CRM fails to convert Agentforce adoption into paid usage.
• Treat CRM’s reported cash generation as a dilution-adjusted metric: monitor SBC relative to operating cash flow and share-count trends. A rising dilution burden alongside slowing core revenue would undermine the lower-multiple case.
• Near-term watch items: Synopsys organic growth excluding acquisition contribution, integration costs and debt trajectory; Salesforce core subscription trends and paid AI adoption. If those disclosures remain opaque, keep positions small rather than underwriting headline growth.